Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
53 hedge funds and large institutions have $101M invested in Biora Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 11 closing their positions.
189% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $7.07M
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
164% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 11
51% more funds holding
Funds holding: 35 → 53 (+18)
39% more capital invested
Capital invested by funds: $72.8M → $101M (+$28.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 2 |
BlackRock
New York
|
+$3.54M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.11M |
| 4 |
Two Sigma Investments
New York
|
+$2.65M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
-$18.8M |
| 2 |
Neuberger Berman Group
New York
|
-$5.62M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.62M |
| 4 |
Renaissance Technologies
New York
|
-$1.24M |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
-$410K |
BIOR Hedge Fund Activity: Q4 2021 in Review
53 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q4 2021, worth a combined $101M — up 39% from $72.8M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BIOR positions and 11 closed out — a net gain of 18 holders — while 17 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.1M. The largest seller was Athyrium Capital Management, cutting an estimated $18.8M.
- 53 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q4 2021, up from 35 in Q3 2021.
- Funds reported $101M of Biora Therapeutics, Inc. Common Stock stock for Q4 2021, up 39% quarter-over-quarter.
- 29 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q4 2021 and 11 closed out, a net change of +18 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $11.1M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q4 2021 was Athyrium Capital Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2021.